Thalys(SH:603716) Sou Hu Cai Jing·2026-01-29 08:49Core Viewpoint - The company, Saili Medical, anticipates a net loss attributable to shareholders of between -160 million RMB and -209 million RMB for the fiscal year 2025, indicating a reduction in losses compared to the previous year [1] Group 1: Financial Performance - The expected net loss for 2025 represents a decrease in losses by 49.2397 million RMB to 2.397 million RMB year-on-year [1] - The primary reason for the performance change is a decline in operating revenue [1] Group 2: Strategic Changes - The company is undergoing a strategic transformation, which includes the transfer of part of its controlling subsidiaries, resulting in these subsidiaries no longer being included in the consolidated financial statements [1] - The decision to not renew certain business contracts after their expiration has also contributed to the decline in operating revenue [1] Group 3: Research and Development - The company is increasing its investment in research and development within the smart medical field, which is impacting profitability due to higher R&D expenses [1]